Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

Annual Report and Accounts for the year ended 30 June 2012

Highlights

Dechra is an international veterinary pharmaceutical business. Our expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide

Revenue

£ million

up 9.5%

Underlying Operating Profit*

£ million

up 15.0%

Underlying Profit Before Taxation*

£ million

up 9.6%

Underlying Earnings per Share*

pence

up 2.7%

Dividend per Share

pence

up 10.3%

Operating Profit

£ million

Profit Before Taxation

£ million

Earnings per Share

pence

* Non-underlying items comprise amortisation of acquired intangibles, acquisition expenses, rationalisation costs, payments to acquire technology for the research and development programme, impairment charges, loss on extinguishment of debt and unwinding of discounts on deferred and contingent consideration (see notes 4 and 5).

† Adjusted for the bonus element of the Rights Issue.

Forward-Looking Statements: This Annual Report contains certain forward-looking statements which reflect the knowledge and information available to the Company during preparation and up to the publication of these Accounts. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future and thereby involving a degree of uncertainty. Therefore, nothing in this publication should be construed as a profit forecast by the Company.

We use cookies and track users anonymously, check this box and save to disable. We are inferring consent by continuing.